Roche loses Risdiplam patent appeal as Indian court cites 'obviousness'
In a landmark win for drug accessibility in India, a court upheld findings that Roche's Risdiplam patent was "obvious" and invalid, thereby allowing Natco Pharma to sell a cheaper generic for...To view the full article, register now.
Already a subscriber? Click here to view full article